HUGO-Nano™: A Human-Framework VHH Mouse Platform with Camelid Hallmark Features
A Human-Framework Approach to VHH Discovery
Traditional VHH discovery commonly relies on immunized camelids, such as llamas and alpacas, to generate naturally occurring single-domain antibodies. While these antibodies offer a compact and versatile molecular format, therapeutic candidates usually require humanization of the camelid framework, particularly in the hallmark framework-2 residues that replace the VH–VL interface so a separate engineering cycle that can cost affinity, stability or both.
HUGO-Nano takes a different approach by combining human-derived antibody variable regions with the camelid VHH hallmark framework-2 residues. With their compact size and modular architecture, HUGO-Nano-derived single-domain antibodies offer potential applications in bispecific and multispecific antibodies, T-cell engagers, CAR-T therapies, antibody conjugates, and molecular imaging. They can also be explored as targeting modules for drug delivery, including blood-brain barrier (BBB)-directed research, depending on the properties of individual antibody candidates.
HUGO-Nano has been characterized using B-cell receptor (BCR) repertoire sequencing, analysis of complementarity-determining region (CDR) sequence diversity, and somatic hypermutation (SHM) measurements. These studies provide molecular evidence of repertoire breadth and in vivo diversification, which can support the discovery of target-specific VHH-like candidates.Together these data show that the engineered locus supports a broad, antigen-responsive repertoire and near-native somatic hypermutation in vivo, the two properties that determine whether a platform can yield high-affinity, target-specific candidates.
HUGO-Nano Antibody Discovery Workflow
HUGO-Nano Antibody Discovery Deliverables & Timeline
| Phase | Service | Deliverables | Timeline |
|---|---|---|---|
| Phase 1: Material Preparation | Protein X | Protein X | 4 weeks |
| Protein X mRNA-LNP | Protein X mRNA-LNP | ||
| Biotinylated protein his Tag | Biotinylated protein his Tag | ||
| Positive control antibody | Positive control antibody | ||
| Phase 2: Mouse Immunization | HUGO-Nano VHH Mice | HUGO-Nano VHH mice with titers meeting the required specifications | 7 weeks |
| Mouse Immunization | Immunization report of HUGO-Nano VHH mice | ||
| ELISA titer detection | ELISA titer data (included in immunization report) | ||
| Cell-based titer detection（optional) | Flow cytometry data (if selected) | ||
| Phase 3: Phage Display VHH Panning | Phage display VHH panning, VHH amplification & sequencing | Phage display panning report; VH/VHH sequences with CDR analysis; phylogenetic tree analysis | 5 weeks |
| Phase 4: Antibody Expression and Validation | Candidate antibody expression, Purification & binding assay | Recombinant VHH antibodies; ELISA antigen binding assay results | 4 weeks |
| ELISA cross-reactivity & Blocking activity assay | ELISA experiment report | ||
| Multi-point SPR affinity detection（optional) | SPR affinity test results (KD(M), kon, koff) | ||
| Cell-based binding activity validation(optional) | Flow cytometry experiment report | ||
| Final report | Research report and antibody sequence list |
How HUGO-Nano Compares with Other Single-Domain Antibody Platforms
| Comparison | Camel / Llama-Derived VHH (Traditional) | Human-VH Mouse / Rat Platforms | Camelid-VHH-in-Mouse Platforms | HUGO-Nano |
|---|---|---|---|---|
| Output | Natural camelid VHH | Human VH sdAb / HCAb | Camelid VHH in mouse | Human-framework VHH-like single-domain antibodies, usable without further humanization |
| Humanization | Usually required | Usually not required for variable domain | Usually required | No additional humanization required |
| Immunogenicity | Moderate before humanization | Generally low | Moderate before humanization | Low predicted immunogenicity (human germline framework) |
| Developability | Strong | More variable | Strong | Tm >60 °C; stable at 40 °C for 14 days |
| Host Practicality | Large-animal workflow | Standard rodent workflow | Standard mouse workflow | Standard mouse workflow |
| Affinity Maturation | Yes | Yes | Yes | Yes |
| Epitope Access | Long CDR3; potential access to cryptic epitopes | Potentially high | Transgene-dependent | Compact structure; potential access to difficult epitopes |
| Speed to Lead | Moderate | High | High for discovery; variable downstream | High; eliminates additional humanization step |
| IP / FTO | Mature but patent-dense | Crowded patent landscape | Platform-specific | FTO-friendly collaboration model |
Key Advantages of HUGO-Nano for Single-Domain Antibody Discovery
- Human-Derived VH Framework with Camelid-Inspired Features: HUGO-Nano combines human-derived antibody variable regions with the camelid VHH hallmark framework-2 residues to generate human-framework, VHH-like single-domain antibodies, removing the downstream humanization cycle that camelid-derived VHHs normally require.
- Efficient In Vivo VHH Antibody Discovery: The genetically engineered mouse platform supports antigen-specific immune responses, antibody repertoire diversification, and in vivo affinity maturation. Combined with phage display or single B-cell screening, it provides a practical workflow for single-domain antibody discovery.
- Developability-Oriented Antibody Design: Engineered VHH-like frameworks support the discovery of independently functioning antibody domains. Tested candidates have shown Tm values above 60 °C and remained stable for 14 days at 40 °C, supporting formulation and further developability assessment.
- Versatile Single-Domain Antibodies for Therapeutic Engineering: The compact, modular architecture of HUGO-Nano-derived antibodies supports their exploration as building blocks for bispecific and multispecific antibodies, T-cell engagers, CAR-T therapies, antibody conjugates, and targeted drug delivery applications.
Case Study
From TFR1-targeting antibody discovery to BBB transport evaluation, explore Cyagen's humanized receptor models, in vitro assays, and preclinical CNS delivery research services.
